What does 96.4% purity on a C18 column actually tell me about a survodutide vial?

Setup, so nobody has to ask: 96.4% · a C18 column · survodutide.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

What can I legitimately conclude from this figure?

Specifically, start by understanding what the detector is measuring and what that means about how the molecule needs to be prepared and handled before injection.

Proline-rich sequences are particularly problematic because the isomerisation kinetics are in the same timescale as the separation, leading to split or broadened peaks at low temperature.

The relevant detail is that trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.

I would caution against over-interpreting small differences between runs, because the noise floor of the method is larger than most people assume.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

Stated carefully, peak shape carries as much information as peak area does, and a badly tailing peak or a shouldered peak is telling you something about the sample or the column that matters.

Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.

Put another way, temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.

The selectivity of a reverse-phase separation depends on the hydrophobicity of the side-chain profile, which is why two peptides can co-elute even if they differ by a residue.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

Mechanically, method transfer between laboratories is almost impossible without full documentation, which is why two labs reporting the same preparation should expect disagreement.

Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.

Ask for the chromatogram and the system suitability data, not just the number.

High-performance liquid chromatography is a separation technique, not an identification technique, and it answers the question "how much of the detected signal is a single species" not "which species is it."

Formic acid is the compromise when you need the mass spectrometer on the same run, but the peak shape penalty is real and easily a tenth of a per cent on purity.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.